Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MB-106 |
Trade Name | |
Synonyms | MB 106|MB106 |
Drug Descriptions |
MB-106 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD20, and containing CD28 co-stimulatory and TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CD20 (Blood (2021) 138 (Supplement 1): 3872; NCI Drug Dictionary). |
DrugClasses | CD20 Immune Cell Therapy 11 |
CAS Registry Number | NA |
NCIT ID | C188358 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MB-106 | MB-106 | 0 | 1 |